Wednesday, December 3, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Blackbaud Emerges as Quiet Performer in Non-Profit Software Sector

Dieter Jaworski by Dieter Jaworski
August 31, 2025
in Earnings, Insider Trading, Tech & Software
0
Blackbaud Stock
0
SHARES
233
VIEWS
Share on FacebookShare on Twitter

While much of the technology sector faces headwinds, Blackbaud has demonstrated remarkable operational resilience. The provider of software solutions for non-profit organizations didn’t just surpass analyst expectations with its second-quarter results—it also significantly raised its full-year guidance, creating an intriguing contrast with recent insider selling activity.

Strong Quarterly Performance Drives Confidence

The company’s operational metrics tell a compelling story of growth and improved efficiency. Blackbaud reported adjusted earnings per share (EPS) of $1.21, substantially exceeding the consensus estimate of $1.05 by 15 percent. Perhaps more significantly, the company achieved 6.8 percent organic growth after excluding impacts from the divestiture of its EVERFI business. This growth was accompanied by dramatically improved profitability, with the adjusted operating margin expanding by 350 basis points to reach 33.5 percent.

Elevated Guidance and Impressive Metrics

Bolstered by this strong quarterly showing, management has upgraded its outlook for the full year. The company now anticipates 2025 adjusted EPS in the range of $4.30 to $4.50, representing approximately 11 percent growth year-over-year. A particularly noteworthy achievement was the company’s “Rule of 40” score—a key industry metric combining growth rate and profitability margin—which reached a quarterly record of 45.3 percent, highlighting Blackbaud’s effective balance between expansion and financial discipline.

Should investors sell immediately? Or is it worth buying Blackbaud?

Institutional and Insider Activity Presents Mixed Picture

Despite these strong operational results, recent trading activity reveals divergent perspectives among key stakeholders. Director Rupal S. Hollenbeck reduced her position by nearly 24 percent in late July, while Executive Vice President Kevin P. Gregoire sold 8,000 shares. Institutional investors also displayed varied approaches: Northern Trust decreased its holdings, while Mitsubishi UFJ Asset Management and UMB Bank substantially increased their positions in the company.

Analyst Sentiment Remains Cautious

Market experts appear to reflect this uncertainty in their assessments. The consensus price target currently sits between $76 and $79, suggesting significant potential upside from current trading levels. However, analyst recommendations present a divided view: of the six analysts covering the stock, only one maintains a buy recommendation, four suggest holding, and one advises selling.

Adding to the complex investment case, Blackbaud has demonstrated committed capital management through a share repurchase program authorizing buybacks of up to 5 percent of outstanding shares, with $545 million still available under the current authorization. The central question for investors remains whether these strong fundamental results can ultimately overcome the skepticism reflected in recent insider transactions and mixed analyst sentiment.

Ad

Blackbaud Stock: Buy or Sell?! New Blackbaud Analysis from December 3 delivers the answer:

The latest Blackbaud figures speak for themselves: Urgent action needed for Blackbaud investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 3.

Blackbaud: Buy or sell? Read more here...

Tags: Blackbaud
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Netflix Stock
Analysis

Netflix Stock: Aggressive Expansion Strategy Takes Shape

December 3, 2025
Innovative Industrial Properties Stock
Analysis

Is Innovative Industrial Properties a Deep-Value Cannabis Play?

December 3, 2025
Nio Stock
Analysis

Nio’s Stock Dilemma: Record Deliveries Meet Investor Skepticism

December 3, 2025
Next Post
PepGen Stock

PepGen Shares Face Mounting Pressure Amid Legal Challenges and Pipeline Shift

Herman Miller Stock

MillerKnoll Navigates Strong Sales and Mounting Headwinds

Cavco Industries Stock

Cavco Industries: The Unseen Leader in Affordable Housing's Surge

Recommended

Capital One Stock

Major Institutions Back Capital One Despite Acquisition Costs

3 months ago
Coca-Cola Stock

Coca-Cola Stock: A Dual-Pronged Growth Strategy Takes Shape

1 week ago
Summit Therapeutics Stock

Summit Therapeutics: Clinical Data Divides Market as CEO Backs Conviction

3 months ago
SunHydrogen Stock

SunHydrogen Reaches Commercial Milestone with First Revenue

3 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

Strategic Moves and Sector Momentum: European Lithium Navigates Shareholder Shifts and Capital Strategy

Netflix Stock: Aggressive Expansion Strategy Takes Shape

Is Innovative Industrial Properties a Deep-Value Cannabis Play?

Is Alibaba’s Stock Dip a Strategic Entry Point?

Intellia Therapeutics Faces Critical Juncture Following Clinical Trial Death

Trending

Novo Nordisk Stock
Analysis

Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures

by Robert Sasse
December 3, 2025
0

The year 2025 is shaping up to be a formidable challenge for Novo Nordisk, with its share...

Ballard Power Stock

Is Ballard Power Stock Nearing an Inflection Point?

December 3, 2025
Redcare Pharmacy Stock

Redcare Pharmacy Shares Continue Their Steep Descent

December 3, 2025
Bionxt Solutions Stock

Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

December 3, 2025
European Lithium Stock

Strategic Moves and Sector Momentum: European Lithium Navigates Shareholder Shifts and Capital Strategy

December 3, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures
  • Is Ballard Power Stock Nearing an Inflection Point?
  • Redcare Pharmacy Shares Continue Their Steep Descent

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com